NVO vs. AZN, NVS, SNY, GSK, TAK, ARGX, BNTX, TEVA, BGNE, and SMMT
Should you be buying Novo Nordisk A/S stock or one of its competitors? The main competitors of Novo Nordisk A/S include AstraZeneca (AZN), Novartis (NVS), Sanofi (SNY), GSK (GSK), Takeda Pharmaceutical (TAK), argenx (ARGX), BioNTech (BNTX), Teva Pharmaceutical Industries (TEVA), BeiGene (BGNE), and Summit Therapeutics (SMMT). These companies are all part of the "pharmaceutical products" industry.
Novo Nordisk A/S vs.
Novo Nordisk A/S (NYSE:NVO) and AstraZeneca (NASDAQ:AZN) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, media sentiment, risk, valuation, dividends, community ranking, analyst recommendations, earnings and institutional ownership.
In the previous week, Novo Nordisk A/S had 19 more articles in the media than AstraZeneca. MarketBeat recorded 60 mentions for Novo Nordisk A/S and 41 mentions for AstraZeneca. Novo Nordisk A/S's average media sentiment score of 0.57 beat AstraZeneca's score of 0.35 indicating that Novo Nordisk A/S is being referred to more favorably in the media.
Novo Nordisk A/S pays an annual dividend of $0.72 per share and has a dividend yield of 0.9%. AstraZeneca pays an annual dividend of $0.98 per share and has a dividend yield of 1.5%. Novo Nordisk A/S pays out 23.3% of its earnings in the form of a dividend. AstraZeneca pays out 46.9% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.
Novo Nordisk A/S received 367 more outperform votes than AstraZeneca when rated by MarketBeat users. Likewise, 61.88% of users gave Novo Nordisk A/S an outperform vote while only 58.82% of users gave AstraZeneca an outperform vote.
Novo Nordisk A/S has a net margin of 35.03% compared to AstraZeneca's net margin of 12.68%. Novo Nordisk A/S's return on equity of 86.32% beat AstraZeneca's return on equity.
11.5% of Novo Nordisk A/S shares are held by institutional investors. Comparatively, 20.4% of AstraZeneca shares are held by institutional investors. 0.1% of Novo Nordisk A/S shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Novo Nordisk A/S has higher earnings, but lower revenue than AstraZeneca. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than AstraZeneca, indicating that it is currently the more affordable of the two stocks.
Novo Nordisk A/S has a beta of 0.45, meaning that its stock price is 55% less volatile than the S&P 500. Comparatively, AstraZeneca has a beta of 0.46, meaning that its stock price is 54% less volatile than the S&P 500.
Novo Nordisk A/S presently has a consensus price target of $140.20, suggesting a potential upside of 78.06%. AstraZeneca has a consensus price target of $89.75, suggesting a potential upside of 34.76%. Given Novo Nordisk A/S's higher probable upside, research analysts plainly believe Novo Nordisk A/S is more favorable than AstraZeneca.
Summary
Novo Nordisk A/S beats AstraZeneca on 13 of the 19 factors compared between the two stocks.
Get Novo Nordisk A/S News Delivered to You Automatically
Sign up to receive the latest news and ratings for NVO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Novo Nordisk A/S Competitors List
Related Companies and Tools
This page (NYSE:NVO) was last updated on 1/20/2025 by MarketBeat.com Staff
